World Orphan Drug Congress Europe
Date : November 12-14, 2019
Speaker : Philip Wills, Chief Commercial Officer, Catalent Biologics | Paragon Gene Therapy
Manufacturing Track Presentation: Capacity crunch? The future of manufacturing within cell & gene therapy
Wednesday, November 13, 2019 |15:20 – 15:50
Abstract:There are many challenges and limitations facing the scale-up and manufacturing of gene therapies in the clinical pipeline today. Rising numbers of clinical trials and FDA approvals, coupled with often low product yields and high treatment costs, means an increase in demand for process expertise and manufacturing capacity. Process optimization, optimal bioproduction systems, and superior manufacturing facilities will be a critical component to the future success of gene therapy products.
Hear Philip Wills, Chief Commercial Officer at Catalent Biologics | Paragon Gene Therapy address capacity limitations and discuss the future of cell & gene therapy manufacturing at the session “Capacity crunch? The future of manufacturing within cell & gene therapy” on Wednesday, November 13, 2019 at 3:20pm at World Orphan Drug Congress Europe.